Establishment of a novel minigenome system for the identification of drugs targeting Nipah virus replication

J Gen Virol. 2024 Jan;105(1). doi: 10.1099/jgv.0.001944.

Abstract

Nipah virus (NiV) is a deadly zoonotic pathogen with high potential to cause another pandemic. Owing to biosafety concerns, studies on living NiV must be performed in biosafety level 4 (BSL-4) laboratories, which greatly hinders the development of anti-NiV drugs. To overcome this issue, minigenome systems have been developed to study viral replication and screen for antiviral drugs. This study aimed to develop two minigenome systems (transient and stable expression) based on a helper cell line expressing the NiV P, N and L proteins required to initiate NiV RNA replication. Stable minigenome cells were resistant to ribavirin, remdesivir and favipiravir but sensitive to interferons. Cells of the transient replication system were sensitive to ribavirin and favipiravir and suitable for drug screening. Our study demonstrates a feasible and effective platform for studying NiV replication and shows great potential for high-throughput drug screening in a BSL-2 laboratory environment.

Keywords: Nipah virus; drug screening; minigenome; persistent transfection; transient transfection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • Nipah Virus* / genetics
  • Ribavirin
  • Virus Replication

Substances

  • favipiravir
  • Ribavirin
  • Antiviral Agents